Clinical genomics promise to be especially suitable for the study of etiologically heterogeneous conditions such as Autism Spectrum Disorder (ASD). Here we present three siblings with ASD where we evaluated the usefulness of Whole Genome Sequencing (WGS) for the diagnostic approach to ASD.
We identified a family segregating ASD in three siblings with an unidentified cause. We performed WGS in the three probands and used a state-of-the-art comprehensive bioinformatic analysis pipeline and prioritized the identified variants located in genes likely to be related to ASD. We validated the finding by Sanger sequencing in the probands and their parents.
Three male siblings presented a syndrome characterized by severe intellectual disability, absence of language, autism spectrum symptoms and epilepsy with negative family history for mental retardation, language disorders, ASD or other psychiatric disorders. We found germline mosaicism for a heterozygous deletion of a cytosine in the exon 21 of the SHANK3 gene, resulting in a missense sequence of 5 codons followed by a premature stop codon (NM_033517:c.3259_3259delC, p.Ser1088Profs*6).
We reported an infrequent form of familial ASD where WGS proved useful in the clinic. We identified a mutation in SHANK3 that underscores its relevance in Autism Spectrum Disorder.
Citation: Nemirovsky SI, Córdoba M, Zaiat JJ, Completa SP, Vega PA, González-Morón D, et al. (2015) Whole Genome Sequencing Reveals a De Novo SHANK3 Mutation in Familial Autism Spectrum Disorder. PLoS ONE 10(2): e0116358. https://doi.org/10.1371/journal.pone.0116358
Academic Editor: Valerie W. Hu, The George Washington University, UNITED STATES
Received: June 6, 2014; Accepted: December 5, 2014; Published: February 3, 2015
Copyright: © 2015 Nemirovsky et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by an unrestricted grant from the Ministry of Science and Technology of the government of Argentina. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Autism spectrum disorder (ASD) is a common cause of early disability, affecting about 1% of the population. It is characterized by impairments in social interaction and communication, as well as by repetitive and restricted behaviors .
ASD is etiologically heterogeneous, with hundreds of highly penetrant genetic aberrations involved as causative factors. Among them, SHANK3 haploinsufficiency has been identified in about 0.5% of subjects with ASD. However, few familial ASD cases caused by mutations in SHANK3 have been identified . Here we present three siblings with ASD where Whole Genome Sequencing (WGS), identified germline mosaicism for a new mutation in SHANK3.
The Ethics Committee of Hospital Ramos Mejía in Buenos Aires, Argentina approved this study. Written informed consents were obtained from the parents of the probands. Clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. The parents of the individuals described in this manuscript gave written informed consent to publish these case details. DNA sequencing data remained stored in a secure internal database, and is available upon request to researchers wishing to use them for research purposes only. Clinical evaluations were performed at the Neurogenetics Unit from Hospital Ramos Mejía.
Genome sequence data generation
Genomic DNA was isolated from peripheral blood and sequenced using 101 base-pair paired-end reversible terminator massively parallel sequencing on an Illumina Hiseq 1500 instrument at INDEAR (Rosario, Argentina), following sequencing library preparation in agreement to standard Illumina protocols. Median fragment length of the libraries was 294 bp. A total of 334.1 Gb with quality equal or more than Q30 was produced for the three genomes. Specifically, 575,427,640 paired-end reads were produced for proband 1 (35.5X coverage), 603,002,568 paired-end reads were produced for proband 2 (37.18X coverage) and 527,754,644 paired-end reads were produced for proband 3 (32.58X coverage).
Sequence Alignment and Annotation
Paired-end reads obtained from sequencing the probands’ whole genomes were aligned to the GRCh37 reference human genome using the Burrows-Wheeler Alignment Tool (BWA) . The resulting SAM files were realigned and recalibrated by implementation of the Genome Analysis Toolkit (GATK) framework [4,5]. Variant calling was performed using the Unified Genotyper tools from GATK. Variant annotation and effect prediction was carried out with SnpEff 3.5a (build 2014-02-14) [6,7] with data from dbSNP Build 138 , the 1000 Genomes Project , the International HapMap Project , the NHGRI GWAS Catalog , dbNSFP v2.3 [12,13], the Exome Sequencing Project (ESP) , and ClinVar Build 20140211 . See S1 Fig.
Bioinformatic Prioritization of candidate variants (see Table 1)
Only high-quality variants (i.e. not filtered out by the GATK’s Variant Quality Score Recalibration method) were considered for the analysis. Those with recorded population frequencies estimates higher than 1% (data from the 1000 Genomes Project and the Exome Sequencing Project) were also discarded as unlikely to be of relevance. From this remaining set, variants with high probability of affecting gene function (frame-shift, nonsense, missense, affecting splice sites and small insertions and deletions) were grouped according to 3 different models of inheritance that may explain the probands’ phenotype: a recessive model grouped homozygous variants or compound heterozygous candidate variants present in the somatic chromosomes, a X-linked model grouped variants from the X chromosome, and a high impact and rare variants model grouped only high impact (nonsense, frame-shift, splice site changes) variants not recorded in the available databases. These groups were filtered through a list of 182 genes known to be of relevance in ASD according to SFARI database  (S1 Table).
Manual Review of Candidate variants
After prioritization, variants considered to possibly explain the phenotype were further investigated individually through the use of several databases and functional evaluation tools which included those provided by NCBI (www.ncbi.nlm.nih.gov), ENSEMBL  (www.ensembl.org/index.html), Mutation Taster  (www.mutationtaster.org), the Combined Annotation Dependent Depletion framework  (cadd.gs.washington.edu) and the Search Tool for the Retrieval of Interacting Genes/Proteins  (STRING; string-db.org), among others.
Three male siblings were included in this study. All of them presented a syndrome characterized by severe intellectual disability, absence of language, autism spectrum symptoms and epilepsy. Family history was otherwise negative for mental retardation, language disorders, ASD or other psychiatric disorders. They were the sole offspring of healthy and unrelated parents after full-term and uneventful pregnancies (Fig. 1A). The mother performed appropriate health checks during gestations and she didn’t show any pathological findings. Deliveries and birth parameters were unremarkable. The eldest proband (III-1 in Fig. 1A) was symptomatic since birth. Neonatal hypotonia was manifested by sucking difficulties and a mild delay in motor development. He had limited eye contact since 6 months of age. He never developed a functional language. He showed severe behavioral problems, motor stereotypes and circumscribed interests since the age of four. He developed epilepsy at the age of 6, suffering from frequent atonic seizure non-respondent to classical antiepileptic drugs. The younger siblings (III-2 and III-3) showed very similar clinical features. They shared dysmorphic features: broad nasal bridge, bulbous nasal root and macrostomia. They exhibited no neonatal hypotonia and showed normal development during their first two years of life with no observable alterations in language. A progressive deterioration started after this age. Language development was arrested, evolving to an almost complete absence of verbal communication. Social interaction became severely impaired. Agitation and repetitive motor behaviors were present since the age of three. Epilepsy with frequent atonic and generalized seizures refractory to medical treatment started at the age of 7 in both siblings. MRIs were normal and some of the several EEGs done showed right-temporal discharges. Standard karyotype and fragile X testing were normal in the three siblings.
Figure 1. A SHANK3 point mutation in three siblings with Autism Spectrum Disorder.
A) Family pedigree depicting the three probands (III-1, III-2, III-3), parents, their siblings and grandparents. B) Mutation as evidenced by whole genome sequencing compared to reference sequence (GRCh37) at bottom. Broad lines represent aligned reads. The heterozygous deletion is depicted as black, thin lines that interrupt the reads. Each panel depicts the data from one proband, C) Capillary sequencing chromatograms of the probands and their parents. A red arrow signals the position of the deletion. The change in ORF is evidenced by the presence of double peaks after the deletion site caused by heterozygocity. D) Linear representations of the intact SHANK3 protein featuring its major domains and the presumptive protein if translated from the mutated sequence. ANK: ankyrin repeats, SH3: SRC Homology 3 domain, PDZ: PDZ domain, Pro: Proline-rich region, SAM: Sterile alpha motif domain.
Whole Genome Analysis
We performed whole genome sequencing of DNA samples from the three siblings, obtaining a mappable yield of 334.1 Gb, which represent an average depth of coverage of 33.04x. We identified more than 4.1 millions of variants in each genome (Table 1). We examined those rare variants (population frequency lower than 1%) in 182 genes associated to ASD (S1 Table) under three possible models of inheritance: recessive, X-linked, high impact de novo mutations (S2 Table, S3 Table). The most plausible candidate to explain the phenotype exhibited by the probands was a heterozygous deletion of a cysteine in the exon 21 of the SHANK3 gene (Fig. 1, B), resulting in a missense sequence of 5 codons followed by a premature stop codon (NM_033517:c.3259_3259delC, p.Ser1088Profs*6). We did not find any difference in SHANK3 mRNA levels in blood among the three affected siblings, their parents and two unrelated controls, suggesting an absence of effect at the transcription level. Therefore, when expressed this protein would lack a Proline-rich region and the Sterile alpha motif (SAM) domain (Fig. 1, D) resulting in a functional haploinsufficiency of SHANK3 protein. Sanger sequencing confirmed this deletion in the three siblings and their absence in DNA purified from blood samples of both parents suggesting germinal mosaicism as the origin of the mutation (Fig. 1, C).
Gene mutations can be identified in about 20% of individuals with ASD . SHANK3 aberrations have consistently been associated with idiopathic and syndromic ASD. However, point mutations in SHANK3 have been rarely reported. A few patients were previously described with only one showing familial recurrence. It has been suggested that nonsense and frameshift mutations in this gene lead to more severe phenotypes  affecting language and development as it was observed in our patients. Moreover, a recent and exhaustive report on the effect of different mutations in the SHANK family of genes in ASD concluded that SHANK3 mutations are probably the most prevalent etiology of ASD with mental retardation and among the different cases described there it is noteworthy to highlight one that have a frameshift deletion predicted to result in a truncated protein lacking the same functional domains that we predict for our mutation, thereby supporting a pathogenic role for the variant here described, precluding the need for more thorough functional assays . The product of this gene is expressed at postsynaptic densities of excitatory glutamatergic synapses and it is involved in synaptic maturation . Moreover, pharmacological restoring of its deficiency is current object of therapeutic research in ASD .
The use of WGS in the clinic is called to be transformative, especially in a complex etiologically heterogeneous disorder such as ASD and intellectual disability . However, recent studies have questioned its readiness for diagnostic adoption mostly because of uncertainties associated with the analysis of such vast amount of information . We have ruled out many variants with a predicted high-impact on protein function because we opted to focus our analysis on genes considered to be of relevance for the phenotype studied therefore decreasing interpretation uncertainties. This left the reported SHANK3 mutation as the sole variant putatively relevant to the phenotype showed in our patients. It is noteworthy to mention that by identifying the pathogenic variant causing the disorder segregating in this family, almost a decade of anxiety associated with diagnostic uncertainties could be alleviated. However, even though we could explain the recurrence of the disorder in the three siblings with the presence of germline mosaicism we could not estimate future recurrence risk because the proportion of germ cells mutated could not be quantified.
In summary, we reported an infrequent form of familial ASD where WGS proved useful in the clinic.
Conceived and designed the experiments: SIN MC MFO AP MM MV AT MAK. Performed the experiments: SIN MC JJZ SPC NMM MF BB S. Romero S. Revale MFO AP MM MV AT MAK. Analyzed the data: SIN MC JJZ SPC NMM MFO AP MM MV AT MAK. Contributed reagents/materials/analysis tools: SIN MC PAV DG MM MV AT MAK. Wrote the paper: SIN MC MM MV AT MAK.
- 1. Lai M-C, Lombardo MV, Baron-Cohen S (2014) Autism. The Lancet 383: 896–910. pmid:24074734
- 2. Betancur C, Buxbaum JD (2013) SHANK3 haploinsufficiency: a “common” but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders. Mol Autism 4: 17. pmid:23758743
- 3. Li H, Durbin R (2010) Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589–595. pmid:20080505
- 4. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297–1303. pmid:20644199
- 5. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43: 491–498. pmid:21478889
- 6. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, et al. (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. Fly (Austin) 6: 80–92. pmid:22728672
- 7. Ruden DM, Cingolani P, Patel VM, Coon M, Nguyen T, et al. (2012) Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Toxicogenomics 3: 35. pmid:22435069
- 8. Sherry ST, Ward M-H, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308–311. pmid:11125122
- 9. Consortium T 1000 GP (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56–65. pmid:23128226
- 10. Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu F, et al. (2003) The International HapMap Project. Nature 426: 789–796. pmid:14685227
- 11. Welter D, MacArthur J, Morales J, Burdett T, Hall P, et al. (2014) The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 42: D1001–D1006. pmid:24316577
- 12. Liu X, Jian X, Boerwinkle E (2011) dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat 32: 894–899. pmid:21520341
- 13. Liu X, Jian X, Boerwinkle E (2013) dbNSFP v2.0: A Database of Human Non-synonymous SNVs and Their Functional Predictions and Annotations. Hum Mutat 34: E2393–E2402. pmid:23843252
- 14. Fu W, O’Connor TD, Jun G, Kang HM, Abecasis G, et al. (2013) Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 493: 216–220. pmid:23201682
- 15. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, et al. (2013) ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res: gkt1113. pmid:24234437
- 16. Basu SN, Kollu R, Banerjee-Basu S (2009) AutDB: a gene reference resource for autism research. Nucleic Acids Res 37: D832–D836. pmid:19015121
- 17. Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, et al. (2013) Ensembl 2013. Nucleic Acids Res 41: D48–D55. pmid:23203987
- 18. Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 11: 361–362. pmid:24681721
- 19. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, et al. (2014) A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46: 310–315. pmid:24487276
- 20. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, et al. (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41: D808–D815. pmid:23203871
- 21. Jeste SS, Geschwind DH (2014) Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat Rev Neurol 10: 74–81. pmid:24468882
- 22. Boccuto L, Lauri M, Sarasua SM, Skinner CD, Buccella D, et al. (2013) Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders. Eur J Hum Genet EJHG 21: 310–316. pmid:22892527
- 23. Leblond CS, Nava C, Polge A, Gauthier J, Huguet G, et al. (2014) Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments. PLoS Genet 10: e1004580. Available: http://dx.doi.org/10.1371/journal.pgen.1004580. Accessed 12 September 2014. pmid:25188300
- 24. Shcheglovitov A, Shcheglovitova O, Yazawa M, Portmann T, Shu R, et al. (2013) SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 503: 267–271. pmid:24132240
- 25. Wang X, Bey AL, Chung L, Krystal AD, Jiang Y-H (2014) Therapeutic approaches for shankopathies. Dev Neurobiol 74: 123–135. pmid:23536326
- 26. Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE (2013) Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 14: 681–691. pmid:23999272
- 27. Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, et al (2014) Clinical interpretation and implications of whole-genome sequencing. JAMA 311: 1035–1045. pmid:24618965
Silverman, J. L., Yang, M., Lord, C. & Crawley, J. N. Behavioural phenotyping assays for mouse models of autism. Nat. Rev. Neurosci.11, 490–502 (2010).
Naisbitt, S. et al. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron23, 569–582 (1999).
Bonaglia, M. C. et al. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am. J. Hum. Genet.69, 261–268 (2001).
Durand, C. M. et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat. Genet.39, 25–27 (2007).
Betancur, C. & Buxbaum, J. D. SHANK3 haploinsufficiency: a “common” but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders. Mol. Autism4, 17 (2013).
Leblond, C. S. et al. Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet.10, e1004580 (2014).
Jiang, Y. H. & Ehlers, M. D. Modeling autism by SHANK gene mutations in mice. Neuron78, 8–27 (2013).
Bozdagi, O. et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol. Autism1, 15 (2010).
Peça, J. et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature472, 437–442 (2011).
Wang, X. et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum. Mol. Genet.20, 3093–3108 (2011).
Kouser, M. et al. Loss of predominant Shank3 isoforms results in hippocampus-dependent impairments in behavior and synaptic transmission. J. Neurosci.33, 18448–18468 (2013).
Duffney, L. J. et al. Autism-like deficits in Shank3-deficient mice are rescued by targeting actin regulators. Cell Rep.11, 1400–1413 (2015).
Wang, X. et al. Altered mGluR5-Homer scaffolds and corticostriatal connectivity in a Shank3 complete knockout model of autism. Nat. Commun.7, 11459 (2016).
Bidinosti, M. et al. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency. Science351, 1199–1203 (2016).
Speed, H. E. et al. Autism-associated insertion mutation (InsG) of SHANK3 exon 21 causes impaired synaptic transmission and behavioral deficits. J. Neurosci.35, 9648–9665 (2015).
Jaramillo, T. C. et al. Altered striatal synaptic function and abnormal behaviour in Shank3 Exon4-9 deletion mouse model of autism. Autism Res.9, 350–375 (2016).
Amodio, D. M. & Frith, C. D. Meeting of minds: the medial frontal cortex and social cognition. Nat. Rev. Neurosci.7, 268–277 (2006).
Delorme, R. et al. Progress toward treatments for synaptic defects in autism. Nat. Med.19, 685–694 (2013).
De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature515, 209–215 (2014).
Chen, J. A., Peñagarikano, O., Belgard, T. G., Swarup, V. & Geschwind, D. H. The emerging picture of autism spectrum disorder: genetics and pathology. Annu. Rev. Pathol.10, 111–144 (2015).
Crawley, J. N., Heyer, W. D. & LaSalle, J. M. Autism and cancer share risk genes, pathways, and drug targets. Trends Genet.32, 139–146 (2016).
Guan, J. S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature459, 55–60 (2009).
Fischer, A., Sananbenesi, F., Mungenast, A. & Tsai, L. H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci.31, 605–617 (2010).
Tsankova, N., Renthal, W., Kumar, A. & Nestler, E. J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci.8, 355–367 (2007).
Grayson, D. R., Kundakovic, M. & Sharma, R. P. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol. Pharmacol.77, 126–135 (2010).
Klimek, V. M. et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res.14, 826–832 (2008).
Piekarz, R. L. et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol.27, 5410–5417 (2009).
Fraczek, J., Vanhaecke, T. & Rogiers, V. Toxicological and metabolic considerations for histone deacetylase inhibitors. Expert Opin. Drug Metab. Toxicol.9, 441–457 (2013).
McPheeters, M. L. et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics127, e1312–e1321 (2011).
Valenta, T., Hausmann, G. & Basler, K. The many faces and functions of β-catenin. EMBO J.31, 2714–2736 (2012).
Murase, S., Mosser, E. & Schuman, E. M. Depolarization drives beta-Catenin into neuronal spines promoting changes in synaptic structure and function. Neuron35, 91–105 (2002).
Yu, X. & Malenka, R. C. Beta-catenin is critical for dendritic morphogenesis. Nat. Neurosci.6, 1169–1177 (2003).
Stoner, R. et al. Patches of disorganization in the neocortex of children with autism. N. Engl. J. Med.370, 1209–1219 (2014).
Han, K. et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature503, 72–77 (2013).
Gilman, S. R. et al. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron70, 898–907 (2011).
Park, E. et al. The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the beta PIX guanine nucleotide exchange factor for Rac1 and Cdc42. J. Biol. Chem.278, 19220–19229 (2003).